ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

FCRF Recompetition Notice Of Intent

September 19, 1980

SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy

November 30, 2012

Going private may allow US Oncology to restructure, respond to Medicare cuts; equity investment firm offers to purchase shares.

April 23, 2004

Rare Lung Disease Raises Risk Of Meningiomas

October 26, 2001

Research Needed To Improve Survival In Adolescents, Young Adults With Cancer

January 26, 2007

Acceptance Of Sentinel Node Biopsy Is Growing, Study Finds

October 31, 2003